title: Inhibitory effects of recombinant IL-4 and recombinant IL-13 on UHMWPE-induced bone destruction in the murine air pouch model.
abstract: OBJECTIVE
  We administered recombinant interleukin (IL)-4 and recombinant IL-13 locally into the air pouch of mice to improve bone resorption induced by ultra-high-molecular-weight polyethylene (UHMWPE) particles.
  
  
  METHODS
  Air pouches were established on the back of BALB/c mice, followed by the surgical introduction of a section of calvaria from a syngeneic mouse donor. We stimulated the bone-implanted pouches with the UHMWPE suspension. We divided UHMWPE-containing mice into four study groups to receive injections of phosphate-buffered saline (control), IL-4 alone, IL-13 alone, or IL-4 and IL-13 into the pouches. We harvested the tissues at 14 d after treatment for molecular and histological analyses.
  
  
  RESULTS
  The inhibitory effect of IL-4 was stronger than that of IL-13 toward osteoclast differentiation and osteoblast for the induction of osteoprotegerin production and down-regulation of receptor for activation of nuclear factor-κB ligand production. Furthermore, the combined treatment with both IL-4 and 1L-13 had a more important role in inhibiting bone resorption in these pouches with UHMWPE stimulation, compared with IL-4 or IL-13 treatment alone.
  
  
  CONCLUSIONS
  Local administration of recombinant IL-4 and IL-13 may be a feasible and effective therapeutic candidate to treat or prevent wear debris-associated osteolysis.
authors.affiliation: Department of Orthopaedics, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Ning-Ning
authors.initials: NN
authors.lastname: Wu
authors.forename: Yu-Qin
authors.initials: YQ
authors.lastname: Mou
authors.forename: Liang
authors.initials: L
authors.lastname: Chen
authors.forename: Zhong-Liang
authors.initials: ZL
authors.lastname: Deng
mesh_terms: D000135:Acid Phosphatase / Q000032:analysis; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D004195:Disease Models, Animal; D005260:Female; D018793:Interleukin-13 / Q000627:therapeutic use*; D015847:Interleukin-4 / Q000627:therapeutic use*; D007527:Isoenzymes / Q000032:analysis; D051379:Mice; D008807:Mice, Inbred BALB C; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects; D010014:Osteolysis / Q000188:drug therapy*; D011095:Polyethylenes / Q000633:toxicity*; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000032:analysis; D011994:Recombinant Proteins / Q000627:therapeutic use; D000071681:Tartrate-Resistant Acid Phosphatase
chemical_list: D018793:Interleukin-13; D007527:Isoenzymes; D011095:Polyethylenes; D053246:Receptor Activator of Nuclear Factor-kappa B; D011994:Recombinant Proteins; C505687:Tnfrsf11a protein, mouse; C111601:ultra-high molecular weight polyethylene; D015847:Interleukin-4; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase